Oridonin exerts protective effects against diabetes-induced renal injury via the Toll-like receptor 4 (TLR4)/p38-mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways [32]. This evidence concerns the gene NFKB1 and diabetes mellitus.